
CDL9 is an original cyclic disulfide липид first designed, synthesized, and functionally validated in the study "in vivo Demonstration of Enhanced mRNA Delivery by Cyclic Disulfide-Containing липид Nanoparticles for Facilitating Endosomal Escape" published in RSC Medicinal Chemistry (DOI: 10.1039/D5MD00084J).Its molecular architecture—featuring a C18:2 di-unsaturated alkyl chain linked to a tertiary amine headgroup modified with an α-lipoic acid-derived cyclic disulfide unit—was explicitly detailed in the paper's липид library. Experimental data from this study demonstrated CDL9’s capacity to boost mRNA delivery efficiency by 6-fold in vitro and 5-fold in vivo when integrated into SM102-based LNPs, leveraging thiol-disulfide exchange for enhanced endosomal escape.
CDL9 is an original cyclic disulfide lipid first designed, synthesized, and functionally validated in the study "In Vivo Demonstration of Enhanced mRNA Delivery by Cyclic Disulfide-Containing Lipid Nanoparticles for Facilitating Endosomal Escape" published in RSC Medicinal Chemistry (DOI: 10.1039/D5MD00084J).Its molecular architecture—featuring a C18:2 di-unsaturated alkyl chain linked to a tertiary amine headgroup modified with an α-lipoic acid-derived cyclic disulfide unit—was explicitly detailed in the paper's lipid library. Experimental data from this study demonstrated CDL9’s capacity to boost mRNA delivery efficiency by 6-fold in vitro and 5-fold in vivo when integrated into SM102-based LNPs, leveraging thiol-disulfide exchange for enhanced endosomal escape.
Вращайте мышью · Колесо — масштаб
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.